Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins
MT10107 is botulinum neurotoxin type A derived drug which utilizes the 150 kDa portion without complexing proteins and human serum albumin contents. To evaluate the efficacy and the safety of MT10107, it was compared with onabotulinumtoxinA in this double-blind, randomized controlled trial. Twenty-f...
Main Authors: | Hyun-Mi Oh, Joo Hyun Park, Dae Heon Song, Myung Eun Chung |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-12-01
|
Series: | Toxins |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6651/8/1/4 |
Similar Items
-
The Safety and Effect of Local Botulinumtoxin A Injections for Long-Term Management of Chronic Pain in Post-Herpetic Neuralgia: Literature Review and Cases Report Treated with Incobotulinumtoxin A
by: Songjin Ri, et al.
Published: (2021-07-01) -
Long-Term Efficacy and Safety of Botulinum Toxin Injections in Dystonia
by: Juan Ramirez-Castaneda, et al.
Published: (2013-02-01) -
Efficacy and Safety of Botulinum Toxin Type A (NABOTA) for Post-stroke Upper Extremity Spasticity: A Multicenter Phase IV Trial
by: Wonjae Hwang, et al.
Published: (2022-08-01) -
Mini-Review on the efficacy and safety of pitavastatin: “The novel seventh statin gaining momentum”
by: Azza Ramadan, et al.
Published: (2022-01-01) -
Efficacy and safety of acupuncture for hand osteoarthritis: study protocol for a multi-center, randomized, sham-controlled clinical trial
by: Weiming Wang, et al.
Published: (2023-02-01)